These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20133255)

  • 21. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.
    Kleer CG; Griffith KA; Sabel MS; Gallagher G; van Golen KL; Wu ZF; Merajver SD
    Breast Cancer Res Treat; 2005 Sep; 93(2):101-10. PubMed ID: 16187229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy.
    Low JA; Berman AW; Steinberg SM; Danforth DN; Lippman ME; Swain SM
    J Clin Oncol; 2004 Oct; 22(20):4067-74. PubMed ID: 15483018
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?
    Anderson WF; Chu KC; Chang S
    J Clin Oncol; 2003 Jun; 21(12):2254-9. PubMed ID: 12805323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.
    Van Laere S; Beissbarth T; Van der Auwera I; Van den Eynden G; Trinh XB; Elst H; Van Hummelen P; van Dam P; Van Marck E; Vermeulen P; Dirix L
    Clin Cancer Res; 2008 Nov; 14(22):7452-60. PubMed ID: 19010862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The epidemiology of inflammatory breast cancer.
    Levine PH; Veneroso C
    Semin Oncol; 2008 Feb; 35(1):11-6. PubMed ID: 18308141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defining the molecular biology of inflammatory breast cancer.
    Charafe-Jauffret E; Tarpin C; Viens P; Bertucci F
    Semin Oncol; 2008 Feb; 35(1):41-50. PubMed ID: 18308145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
    Gralow JR; Burstein HJ; Wood W; Hortobagyi GN; Gianni L; von Minckwitz G; Buzdar AU; Smith IE; Symmans WF; Singh B; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):814-9. PubMed ID: 18258991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.
    Roy V; Perez EA
    Breast Cancer Res Treat; 2009 Jul; 116(1):31-8. PubMed ID: 19101790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [High-throughput quantification of tissue microarrays: identification of candidate target proteins in inflammatory breast cancer].
    Taranger-Charpin C; Andrac-Meyer L; Dales JP; Carpentier-Meunier S; Andonian C; Lavaut MN; Allasia C; Bonnier P
    Bull Acad Natl Med; 2007 Feb; 191(2):361-74; discussion 374-6. PubMed ID: 17969554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the treatment of breast cancer.
    Moulder S; Hortobagyi GN
    Clin Pharmacol Ther; 2008 Jan; 83(1):26-36. PubMed ID: 18091763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The paradox of triple negative breast cancer: novel approaches to treatment.
    Fornier M; Fumoleau P
    Breast J; 2012; 18(1):41-51. PubMed ID: 22098334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies: the French experience.
    Viens P; Tarpin C; Roche H; Bertucci F
    Cancer; 2010 Jun; 116(11 Suppl):2829-36. PubMed ID: 20503415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer.
    Generali D; Symmans WF; Berruti A; Fox SB
    J Natl Cancer Inst Monogr; 2011; 2011(43):99-102. PubMed ID: 22043052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on systemic treatment for newly diagnosed inflammatory breast cancer.
    Chainitikun S; Saleem S; Lim B; Valero V; Ueno NT
    J Adv Res; 2021 Mar; 29():1-12. PubMed ID: 33842000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular determinants of the inflammatory breast cancer phenotype.
    Houchens NW; Merajver SD
    Oncology (Williston Park); 2008 Dec; 22(14):1556-61; discussion 1561, 1565-8, 1576. PubMed ID: 19198217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Inflammatory breast carcinoma: towards molecular characterization?].
    Charafe-Jauffret E; Tarpin C; Ginestier C; Bertucci F; Penault-Llorca F; Xerri L; Birnbaum D; Viens P; Hassoun J; Jacquemier J
    Ann Pathol; 2003 Dec; 23(6):564-9. PubMed ID: 15094594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammatory breast cancer: an overview.
    van Uden DJ; van Laarhoven HW; Westenberg AH; de Wilt JH; Blanken-Peeters CF
    Crit Rev Oncol Hematol; 2015 Feb; 93(2):116-26. PubMed ID: 25459672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What progress have we made in managing inflammatory breast cancer?
    Dawood S; Cristofanilli M
    Oncology (Williston Park); 2007 May; 21(6):673-9; discussion 679-80, 686-7. PubMed ID: 17564325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.